Amgen Canada Inc. et al v. Sandoz Canada Inc.
2022
T-1838-22
Pending
New PM(NOC) Regulations
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,589,765, 2,589,921, 2,701,778, 2,741,312 and 2,873,044 (carfilzomib).
Counsel to:
Sandoz Canada Inc.
The decision is reported
here.
Meet the team
![Warren Sprigings](https://cdn.prod.website-files.com/5d9fc778718dbe2981337802/5da0b602718f3580ecb0cc1e_warren-bw-min.jpg)
Warren Sprigings
Partner
![Mingquan Zhang, Ph.D.](https://cdn.prod.website-files.com/5d9fc778718dbe2981337802/5da0bad553dd20fa3025675b_ming-bw-min.jpeg)
Mingquan Zhang, Ph.D.
Associate
![Meghan A. Dureen, Ph.D.](https://cdn.prod.website-files.com/5d9fc778718dbe2981337802/5da0bae05e71cd3af89ae952_meghan-bw-min.jpeg)
Meghan A. Dureen, Ph.D.
Counsel
![Alexandre Lavoie](https://cdn.prod.website-files.com/5d9fc778718dbe2981337802/5f3588452d3c6c32143ccddb_alavoie.jpg)
Alexandre Lavoie
Associate